

# Complex renal cystic masses: current standards and controversies

Peter Weibl · Tobias Klätte · Matthias Waldert · Mesut Remzi

Received: 4 May 2010 / Accepted: 18 October 2010 / Published online: 26 November 2010  
© Springer Science+Business Media, B.V. 2010

**Abstract** Bosniak classification system is the only preoperative diagnostic tool that has proven its efficiency in the management of complex renal cystic masses. However, it is reader dependent, despite its clear definition of each category. The overall incidence of malignancy in each category did not change significantly over the past 20 years. Current limitations are interobserver variability among readers and a fact that a significant proportion of Bosniak III masses have benign character. The goal is to depict these masses preoperatively and spare the patients of unnecessary surgeries, which raises the question: What particular findings will help in differentiating a Bosniak IIF lesion from a Bosniak III lesion? Do we need to define critical variables that could improve accuracy of Bosniak classification by developing a future nomogram or risk calculator? Some radiologists and urologists erroneously tend to group Bosniak II and IIF in one category and observe them regularly. It seems that radiographic growth itself is insufficient factor for intervention. The change of internal architecture and presence of enhancement play the most important role in depicting malignant lesions during the time frame of active surveillance.

**Keywords** Kidney · Renal cyst · Complex renal · Renal cell cancer · Bosniak classification

## Introduction

Cystic renal masses are usually classified according to the Bosniak classification. It was introduced in 1986, later modified and is now accepted by urologists and radiologists worldwide [1]. Five groups have been delineated including I, II, IIF, III, and IV. The Bosniak classification is based on findings of contrast-enhanced computed tomography (CT), but can be also applied for MRI [1]. MRI in most circumstances offers no advantage over CT. However, in some cases, MRI can better demonstrate the septa and wall thickening when compared with CT [2]. In contrast, ultrasound plays a limited role in classifying cystic renal masses [1]. New technical improvements, such as contrast enhanced US may play a limited role in patients who are at risk for injection of iodinated or MR contrast media.

Details of the current classification are shown in (Table 1). Generally, management of renal cysts is largely dependent on the assigned group; however, there are still controversies in diagnosis and management of these lesions.

The basic morphological features of complex renal cysts are the presence of: (1) septa; (2) calcifications; (3) nodular or solid structures; and (4) enhancement. In the past, the presence of thick, nodular or irregular

P. Weibl (✉) · T. Klätte · M. Waldert · M. Remzi  
Department of Urology, Medical University of Vienna,  
AKH, Währinger Gürtel 18-20, 1090 Vienna, Austria  
e-mail: pweibl@yahoo.com

**Table 1** Bosniak classification of renal cysts [1]

Group	Description
I	A benign simple cyst with a hairline thin wall that does not contain septa, calcifications, or solid components. It measures water density and does not enhance
II	A benign cyst that may contain a few hairline thin septa in which “perceived” enhancement may be present. Fine calcification or a short segment of slightly thickened calcification may be present in the wall or septa. Uniformly high-attenuation lesions <3 cm (so-called high-density cysts) that are well margined and do not enhance are included in this group. Cysts in this category do not require further evaluation
IIF	Cysts that may contain multiple hairline thin septa or minimal smooth thickening of their wall or septa. Perceived enhancement of their septa or wall may be present. Their wall or septa may contain calcification that may be thick and nodular, but no measurable contrast enhancement is present. These lesions are generally well margined. Totally intrarenal nonenhancing high-attenuation renal lesions >3 cm are also included in this category. These lesions require follow-up studies to prove benignity
III	“Indeterminate” cystic masses that have thickened irregular or smooth walls or septa in which measurable enhancement is present. These are surgical lesions, although some will prove to be benign (e.g. hemorrhagic cysts, chronic infected cysts, and multiloculated cystic nephroma), some will be malignant, such as cystic renal cell carcinoma and multiloculated cystic renal cell carcinoma
IV	These are clearly malignant cystic masses that can have all the criteria of category III, but also contain enhancing soft-tissue components adjacent to, but independent of, the wall or septum. These lesions include cystic carcinomas and require surgical removal

**Table 2** The mean values of calcification scores in each Bosniak category [3]

Bosniak category	No. of masses	No. of malignant masses vs. benign	No. of benign masses determined by follow-up	Mean length of follow-up (months)	Mean value of calcification score
II	21	No surgery	6	61	1.4
IIF	19	3	16	68	3.1
III	25	9/12	4	37	2.1
IV	16	16/0	0	/	2.2

calcifications has placed the lesion into surgical Bosniak III category. Israel et al. have proved that according to the presence of calcifications alone, a lesion should not be classified as surgical. In their study, the value of calcification score was similar between surgical and non-surgical lesions [3] (Table 2). Therefore, the presence of thick, irregular calcifications may upgrade the Bosniak II lesion into Bosniak IIF category. The presence of enhancement is considered as the critical parameter to separate potentially benign from malignant lesions. It also seems that enhancement is one of the major determinants of progression for depicting malignant lesions during observation [4–7].

Diagnosis and management of Bosniak I and IV lesions is straightforward and usually leads to expectant or surgical management, respectively. Bosniak IIF masses, however, harbor a significant risk of renal cell carcinoma (RCC) that may be as

high as 24% [4, 5, 7, 8] (Table 3). At most institutions, these cysts are only explored when they progress over time or become symptomatic. In Bosniak III category, a significant proportion of masses are malignant (0–100%, generally up to 50% are benign) [8–12] (Table 3). Differentiation of the malignant Bosniak III from benign masses on imaging is crucial in order to avoid unnecessary surgeries. The main problem from 1986 till 1993 was to differentiate some complicated Bosniak II from Bosniak III lesions. Bosniak II lesions that have some worrisome features (but not enough to categorize them to Bosniak III group) were suggested and designated as Bosniak IIF lesions [13] to establish their character during regular observation with CT or MRI. Certainly, this new category was beneficial and increased the incidence of malignancy in Bosniak III category [6], but could potentially increase the interobserver variability. Regular follow-up of CT,

**Table 3** Incidence of malignancy in each Bosniak category, when considering that the observed lesions in Bosniak III and IV class are malignant

References	Bosniak category /numberof masses			
	Bosniak II	Bosniak IIF	Bosniak III	Bosniak IV
Brown et al. [15]	0/4	–	3/12	4/6
Aronson et al. [16]	0/4	–	4/7	5/5
Bellman et al. [9]	0/5	–	0/5	–
Cloix et al. [17]	1/7	–	4/13	7/10
Wilson et al. [18]	4/5	–	4/4	6/6
Siegel et al. [19]	1/8	–	5/11	26/29
Bielsa et al. [20]	1/8	–	7/9	3/3
Koga et al. [10]	1/2	–	10/10	12/12
Curry et al. [21]	0/11	–	29/49	18/18
Limb et al. [22]	3/28	–	8/29	–
Spaliviero et al. [11]	2/9	1/4	6/12	19/21
Song et al. [12]	3/26	0/3	21/38	32/37
Overall number malignant vs. benign	16/117	1/7	101/199	133/147
Incidence of malignancy (%)	13.7	14.3	50.8	90.1

Studies with biopsy of complex renal cystic masses or those that had tendency to group Bosniak II/IIF or II and III as indeterminate masses into one category were not included in analysis. Studies regarding the follow-up of moderately complex cystic renal masses were also excluded from analysis, because the vast majority of lesions lack pathological correlation

apart from the added expense, additional radiation exposure has potential, albeit low a risk of developing secondary malignancies.

[14]. Although the Bosniak classification system is the only preoperative diagnostic tool that has proven its efficiency in the management of complex renal cystic masses (CRCM), it is highly reader dependent despite clear definition of each category.

In this review, the authors point out diagnostic dilemmas and current controversies in the management of CRCM.

#### Bosniak II and IIF controversies

Follow-up of Bosniak IIF cystic masses has been proven as a safe management. Minimum of 5-year follow-up is important to determine the stability and benign nature of the mass. When the lesion progresses (in terms of enhancement, change in internal architecture by developing irregular, thick enhancing septa, solid component or multilocular character) on control CT scan or MRI, the lesion is upgraded and indicated for surgical revision [4]. Three patients from our group progressed, and the detection and presence of CT enhancement was the major indicator

for surgery. Final histopathology confirmed RCC in all cases [23]. Similar results were recently observed by Gabr. et al., where 7 pts with Bosniak II and IIF progressed in terms of size, complexity, or enhancement. In 3 cases (1 pt with Bosniak II and 2 pts with Bosniak IIF), enhancement was detected as the parameter of progression, final histology confirmed malignancy [5].

Bosniak II and IIF cysts harbor more than 10% risk of having carcinoma (Table 3). The overall incidence of malignancy in both groups can be presumed to be much lower, because most of the masses are generally followed and only few of them are surgically resected.

Recently published study by O'Malley et al., with the largest cohort of Bosniak IIF lesions, has demonstrated 14.8% rate of progression. Three patients were lost on follow-up, 4 patients are still observed, while the progression was considered marginal or pts are in poor medical condition and in 5 surgically managed patients, RCC was confirmed [6] (Table 4).

The overall incidence of malignancy in Bosniak IIF can be influenced by interobserver variability, number of surgically resected lesions, presumed

**Table 4** Incidence of malignancy in Bosniak IIF based on number of surgically resected lesions and benignity presumed on radiographic stability of the remaining lesions

Author	Bosniak group	Number of lesions	Mean F/U	No. of progressed lesions/Type of progression	No. of surgical interventions	Malignant vs. benign surgical interventions	Incidence of malignancy based on surgical interventions only	Overall incidence of malignancy
Israel et al. [4]	IIF	42	5.8	7 (2-thicker septa) (3-more calcifications)	3 (2) (1)	2/1 (2/0) (0/1)	66.7%	4.7%
Gabir et al. [5]	II/IIF	50	3.1	7 [3-minimally complex (2-increase in size) (1-onset of flank pain) 4-moderately complex (1-increased heterogeneity and growth) (1-development of thick enhancing wall and growth) (2-development of enhancing nodule)]	7 (2) (1) (1) (4)	5/2 (1/1) (0/1) (4/0)	100%	No calculation/ Bosniak II/IIF are grouped together in this study
O'Malley et al. [6]	IIF	81	1.9	12 (was not closely specified in this study)	5	5/5	100%	6.2%
Weibl et al. [7]	IIF	15	4.1	3 (3-enhancement)	3	3/0	100%	20%

benign character based on radiographic stability, length of follow-up and the character of progression as well. Generally, increase in size does not result in surgical procedure. For that reason, it seems important to define the most accurate parameters of progression as the indicator for intervention in Bosniak II and IIF group (Table 4); furthermore, some radiologists tend to group these lesions in one category [5].


#### Major and minor criteria of Bosniak III lesions

Bosniak III lesion is a surgical lesion indicated for intervention, but the current dilemma is that significant proportion of benign lesions are in this category. The known interobserver variability was proved to be highest among Bosniak II and III masses [19]; however, Bosniak IIF category was not evaluated in that study. Recently Weibl [23] and Quiaia et al. [24].showed a high rate of variability between Bosniak II, IIF and III groups.

In some cases, the management of Bosniak III mass may vary from center to center, regardless of the fact the Bosniak III is a surgical mass.

In some specific cases, one may seek for further diagnostic evaluation, such as: mass is indeterminate on CT [Fig. 1], young patients with completely intrarenal mass, which limits the nephron sparing procedure, relatively young patients with solitary kidney or on the contrary patients with short-term survival. In these cases, probably the indication for surgery will not be so straightforward or absolute.

Dedicated 4-phase CT scan or MRI is the basic tool for categorizing CRCM according to the Bosniak classification. Biopsy may be contributory especially when the infectious nature of the mass is suspected. However, negative biopsy does not exclude malignancy, that the lesion is not malignant, what is certainly frustrating as well for the urologist as for the patient. Role of biopsy of small renal masses and complex renal cysts is controversial [25], even though some authors recommend biopsy of indeterminate or Bosniak III masses with favorable results [26–28]. To date, there is no general consensus. The results of upcoming biopsy studies with potential oncomarkers may bring some new answers [29]. Even though biopsy or aspiration cytology in borderline cystic renal masses should be considered as one possible variable included in the development of



**Fig. 1** Diagnostic and therapeutic protocol for Bosniak III—potential further evaluations according to the literature data

risk calculator or a nomogram. Additionally integration of parameters such as age, ASA score, initial size, enhancement, growth rate and type of progression improves the decision-making process.

Active surveillance of surgical, potentially malignant complex renal cystic lesions is still considered to be experimental. High-risk patients with multiple comorbidities, with short-term overall survival and those who refuse any kind of intervention are potential candidates for this management. Long- and mid-term follow-up data are lacking. Until today, there is no clear consensus about the growth rate that warrants intervention for masses under active surveillance. That is why the growth itself is a not reliable and accurate predictor of malignancy and surgical intervention. As mentioned previously, again combination of more variables should improve the accuracy for intervention (size, radiographic growth, symptoms, type of progression, especially change in internal architecture of the cystic lesion).

## Conclusion

Bosniak classification system has been established in 1986, proved its efficiency, but even after more than 20 years of clinical experience has some limitations. Current dilemmas and improvements are needed especially in Bosniak III category, because a significant

proportion have benign character. Limitation such as interobserver variability among various readers with different levels of experience could be potentially improved by developing a nomogram or a risk calculator. The goal is to specify which variables are the most relevant and accurate to be included in such a development. It is not a rare phenomenon that some urologist and radiologists tend to group some Bosniak II and IIF lesions in one category and observe them regularly. The crucial role in this group of patients is playing the parameters of progression. The radiographic growth itself is not a sufficient factor for intervention. The change of internal architecture and presence of enhancement play the most important role in depicting malignant lesions during the time frame of active surveillance.

**Conflicts of interest** I hereby certify that the manuscript or portions thereof are not under considerations by another journal or electronic publication and have not been previously published. Authors fully support this statement. The authors declare that they have no conflict of interest.

## References

1. Israel GM, Bosniak MA (2005) An update on the Bosniak classification system. *Urology* 66(3):484–488
2. Israel GM, Hindman N, Bosniak MA (2004) Evaluation of cystic masses: comparison of CT and MR imaging by using the Bosniak classification system. *Radiology* 231(2):365–371
3. Israel GM, Bosniak MA (2003) Calcification in cystic renal masses: is it important in diagnosis? *Radiology* 226:47–521
4. Israel GM, Bosniak MA (2003) Follow-up CT of moderately complex cystic lesions of the kidney (Bosniak category IIF). *AJR* 181:627–633
5. Gabr AH, Gdor Y, Roberts WW, Wolf JS Jr (2008) Radiographic surveillance of minimally and moderately complex renal cysts. *BJU Int* 103:1116–1119
6. O'Malley RL, Godoy G, Hecht EM, Stifelman MD, Taneja SS (2009) Bosniak category IIF designation and surgery for complex renal cysts. *J Urol* 182:1091–1095
7. Weibl P, Lutter I, Breza J (2006) Follow-up of complex cystic lesions of the kidney Bosniak type II/IIF. *Eur Urol Suppl* 5(2):70
8. Wolf J Jr (1998) Evaluation and management of solid and cystic renal masses. *J Urol* 159(4):1120–1133
9. Bellman GC, Yamguchi R, Kaswick J (1995) Laparoscopic evaluation of indeterminate renal cysts. *Urology* 45(6):1066–1070
10. Koga S, Nishikido M, Inuzuka S, Sakamoto I, Hayashi T, Hayashi K, Saito Y, Kanetake H (2000) An evaluation of

- Bosniak classification of cystic renal masses. *BJU Int* 86: 607–609
11. Spaliviero M, Herts BR, Magi-Galluzzi C, Xu M, Desai M, Kaouk J, Tucker K, Steinberg AP, Gill I (2005) Laparoscopic partial nephrectomy for cystic masses. *J Urol* 714: 614–619
  12. Song Ch, Min GU, Song K, Kim JK, Hong B, Kim CS, Hanjong A (2009) Differential diagnosis of complex cystic renal mass using multiphase computerized tomography. *J Urol* 181(6):2446–2450
  13. Bosniak MA (1993) Problems in the radiologic diagnosis of renal parenchymal tumors. In: Olsson CA, Sawczuk IS (eds) *The urologic clinics of North America*. Saunders, Philadelphia, pp 217–230
  14. Brenner DJ, Hall EJ (2007) Computed tomography—an increasing source of radiation exposure. *New Engl J Med* 357(22):2277–2284
  15. Brown WC, Amis ES Jr, Kaplan SA, Blaiwas JG, Axelrod SL (1989) Renal cystic lesions: predictive value of preoperative computerized tomography. *J Urol* 141:426A
  16. Aronson S, Frayrier HA, Baluch JD, Hartman DS, Christenson PJ (1991) Cystic renal masses: usefulness of the Bosniak classification. *Urol Radiol* 13(2):83–90
  17. Cloix P, Martin X, Pangaud C, Marechal JM, Bouvier R, Barat D, Dubernard JM (1996) Surgical management of complex renal cysts: a series of 32 cases. *J Urol* 3:564–570
  18. Wilson TE, Doelle EA, Cohan RH, Wojno K, Korobkin M (1996) Cystic renal masses: a reevaluation of the usefulness of the Bosniak classification system. *Acad Radiol* 3:564–570
  19. Siegel CL, McFarland EG, Brink JA, Fisher AJ, Humphrey P, Heiken JP (1997) CT of cystic renal masses: analysis of diagnostic performance and interobserver variation. *AJR Am J Roentgenol* 169:813–818
  20. Bielsa GO, Arango TO, Cortadellas AR, Castro SR, Griñó Garreta J, Gelabert-Mas A (1999) The preoperative diagnosis of complex renal cystic masses. *Arch Esp Urol* 52(1):19–25
  21. Curry NS, Cochran ST, Bissada NK (2000) Cystic renal masses: accurate Bosniak classification requires adequate renal CT. *AJR Am J Roentgenol* 175:339–342
  22. Limb J, Santiago L, Kaswick J, Bellman GC (2002) Laparoscopic evaluation of indeterminate renal cysts: long-term follow-up. *J Endourol* 16(2):79–82
  23. Weibl P, Klatte T, Kollarik B, Geryk B, Schueller G, Marberger M, Remzi M (2010) Complex renal cystic masses: interpersonal variability of Bosniak classification is significant—fact or fiction. *Eur Urol Suppl* 9(2):298
  24. Quaia E, Bertolotto M, Cioffi V, Rossi A, Baratella E, Pizzolato R, Cova MA (2008) Comparison of contrast-enhanced sonography with unenhanced sonography and contrast enhanced CT in the diagnosis of malignancy in complex cystic renal masses. *AJR* 191:1239–1249
  25. Remzi M, Marberger M (2009) Renal tumor biopsies for evaluation of small renal tumors: why, in whom, and how? *Eur Urol* 55(2):359–367
  26. Harisinghani MG, Maher MM, Gervais DA, McGovern F, Hahn P, Jhaveri K, Varghese J, Mueller PR (2003) Incidence of malignancy in complex cystic renal masses (Bosniak category III): Should imaging-guided biopsy precede surgery? *AJR* 180:755–758
  27. Lang EK, Macchia RJ, Gayle B, Richter F, Watson RA, Thomas R, Myers L (2002) CT-guided biopsy of indeterminate renal cystic masses (Bosniak 3 and 2F): accuracy and impact on clinical management. *Eur Radiol* 12: 2518–2524
  28. Lechevalier E, Andre M, Barriol D, Daniel L, Eghazarian C, Fromont MD, Rossi D, Coulange C (2000) Fine-needle percutaneous biopsy of renal masses with helical CT guidance. *Radiology* 216:506–510
  29. <http://clinicaltrials.gov/show/NCT00491621> Study ID Number: 0501106